Brigatinib and cetuximab combination prolongs median PFS compared with chemotherapy alone in NSCLC patients with EGFR-activating mutation, T790M, and cis-C797S triple mutations (Wang et al., 2020). Here, EGFR is linked to non-small cell lung carcinoma.